Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Synergistic Antitumor Effect of Nvp-Bez235 and Cape on Mda-Mb-231 Breast Cancer Cells Publisher Pubmed



Torki S1 ; Soltani A1 ; Shirzad H2 ; Esmaeil N3 ; Ghatrehsamani M1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Cellular and Molecular Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran
  2. 2. Medical Plants Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran
  3. 3. Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Source: Biomedicine and Pharmacotherapy Published:2017


Abstract

Triple negative breast cancer (TNBC) is the most lethal and aggressive kind of breast cancer. Studies with TNBC cells suggest that tumor environmental cytokines such as Transforming Growth Factor β1 (TGF-β1) have important roles in tumors fate. In the present study, we aimed to investigate, the effect of phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathway dual inhibitor, NVP-BEZ235 and Caffeic acid phenyl ester (CAPE) on TNBC cell line (MDA-MB-231), stimulated with TGF-β1 for 14 days in vitro. We found that TGF-β1 as a local tumor environmental cytokine plays important role in the progression and invasiveness of TNBC cells. NVP-BEZ235 inhibited the enhanced cell viability and CXCR4 expression induced by TGF-β1. In addition, the combined treatment of TNBC cell lines with CAPE and NVP-BEZ235 synergistically inhibited cell growth and reduced CXCR4 expression. Also, treatment of MDA-MB-231 cells with CAPE and NVP-BEZ235 led to decreasing the expression levels of p-FOXO3a in a time-dependent manner. Overall, these results suggest that tumor metastasis and progression in TNBC cells can be effectively reduced through the concurrent use of NVP-BEZ235 and CAPE. This could be of particular interest in assessing the effects of this therapy in the reduction of tumor metastasis and progression in other tumor types. © 2017 Elsevier Masson SAS
Other Related Docs
22. The Role of Lncrna Mcm3ap-As1 in Human Cancer, Clinical and Translational Oncology (2023)
32. Prediction of Dual Nf-Κb/Iκb Inhibitors Using an Integrative In-Silico Approaches, Journal of Biomolecular Structure and Dynamics (2023)